dsRNA Lipid Complex for Complement C5 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with excessive activation of complement C5, such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, rely on expensive monoclonal antibodies like eculizumab, necessitating the development of alternative methods to inhibit complement C5 expression effectively.
Innovation Solution
A novel double-stranded ribonucleic acid (dsRNA) and a lipid complex encapsulating the dsRNA are developed, specifically designed to target and suppress the expression of complement C5 by using specific sense and antisense strand combinations, which are encapsulated in a lipid complex comprising cationic lipids and other lipids for enhanced delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies like eculizumab are used to inhibit complement C5, then therapeutic effect is achieved, but treatment cost becomes very expensive
Solution Approach 1:
The patent replaces expensive monoclonal antibodies with dsRNA molecules that can be synthesized at lower cost. The dsRNA induces RNA interference to suppress complement C5 expression, providing a more affordable alternative while maintaining therapeutic effectiveness for diseases like PNH and aHUS
Solution Approach 2:
The patent substitutes the mechanical/chemical binding mechanism of monoclonal antibodies with the biological RNA interference mechanism. Instead of using antibody-C5 protein binding, the invention uses dsRNA to trigger RISC complex formation that cleaves C5 mRNA, thereby reducing treatment cost while achieving the same therapeutic goal
2Ease of manufacture
If dsRNA is used to suppress complement C5 expression, then treatment cost is reduced, but delivery efficiency and stability may be compromised
Solution Approach 1:
The patent combines dsRNA with lipid molecules to form lipid-dsRNA complexes. This composite structure protects the dsRNA from degradation by nucleases in the bloodstream, improves cellular uptake efficiency, and enhances overall delivery performance while maintaining the cost advantage of dsRNA over monoclonal antibodies
Solution Approach 2:
The lipid complex serves as an intermediary carrier that facilitates dsRNA delivery into target cells. The lipid component mediates the interaction between dsRNA and cell membranes, enabling efficient intracellular delivery without compromising the therapeutic efficacy or increasing treatment cost
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dsRNA effectively suppresses complement C5 expression, providing a therapeutic option for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, potentially offering a more affordable and effective treatment compared to existing monoclonal antibody therapies.
Implementation Method 1
double-stranded ribonucleic acid (dsRNA) agents are known, which induce cleavage of an RNA transcript of the C5 gene via an RNA-induced silencing complex (RISC)
Implementation Method 2
a lipid complex encapsulating the double-stranded ribonucleic acid
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided is a double-stranded ribonucleic acid comprising a combination of sense strand and antisense strand, wherein the combination of the sense strand and antisense strand are selected from the group consisting of combinations: SEQ ID NO: 159 and 160, SEQ ID NO: 141 and 142, SEQ ID NO: 143 and 144, SEQ ID NO: 145 and 146, SEQ ID NO: 147 and 148, and SEQ ID NO: 153 and 154.